Natural History of NAFLD/NASH

Current Hepatology Reports

Volumn 16, Issue 4, 2017, Pages 391-397

  Ekstedt, Mattias ^a   Nasr, Patrik ^a   Kechagias, Stergios ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Liver histology; Mortality; Natural history; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Prognosis

Indexed keywords

EID: 85051971741     PISSN: None     EISSN: 21959595     Source Type: Journal    
DOI: 10.1007/s11901-017-0378-2     Document Type: Article

References (57)

1. Z.M. Younossi A.B. Koenig D. Abdelatif Y. Fazel L. Henry M. Wymer Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes Hepatology 2016 64 1 73 84 10.1002/hep.28431 26707365
2. L. Li D.W. Liu H.Y. Yan Z.Y. Wang S.H. Zhao B. Wang Obesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies Obes Rev 2016 17 6 510 519 1:CAS:528:DC%2BC28XntlSksbg%3D 10.1111/obr.12407 27020692
3. Y. Chang H.S. Jung J. Cho Y. Zhang K.E. Yun M. Lazo et al. Metabolically healthy obesity and the development of nonalcoholic fatty liver disease Am J Gastroenterol 2016 111 8 1133 1140 1:CAS:528:DC%2BC28XhtlSmsbzO 10.1038/ajg.2016.178 27185080
4. S. Zelber-Sagi R. Lotan A. Shlomai M. Webb G. Harrari A. Buch et al. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up J Hepatol 2012 56 5 1145 1151 10.1016/j.jhep.2011.12.011 22245895
5. C.D. Williams J. Stengel M.I. Asike D.M. Torres J. Shaw M. Contreras et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study Gastroenterology 2011 140 1 124 131 10.1053/j.gastro.2010.09.038 20858492 One of the very few studies that investigate the prevalence of NASH in the general population.
6. H. Yki-Järvinen Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome Lancet Diabetes Endocrinol 2014 2 11 901 910 10.1016/S2213-8587(14)70032-4 24731669
7. S.K. Park M.H. Seo H.C. Shin J.H. Ryoo Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study Hepatology 2013 57 4 1378 1383 1:CAS:528:DC%2BC3sXlslygtL8%3D 10.1002/hep.26183 23213066
8. Q.M. Anstee G. Targher C.P. Day Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis Nat Rev Gastroenterol Hepatol 2013 10 6 330 344 1:CAS:528:DC%2BC3sXptVOlsrs%3D 10.1038/nrgastro.2013.41 23507799
9. Björkström K, Stål P, Hultcrantz R, Hagström H. Histologic scores for fat and fibrosis associate with development of type 2 diabetes in patients with non-alcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2017; https://doi.org/10.1016/j.cgh.2017.04.040.
10. R. Pais A.S. Barritt Y. Calmus O. Scatton T. Runge P. Lebray et al. NAFLD and liver transplantation: current burden and expected challenges J Hepatol 2016 65 6 1245 1257 10.1016/j.jhep.2016.07.033 27486010 5326676
11. Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or MRE to detect fibrosis in patients with non-alcoholic fatty liver disease: a meta-analysis. Hepatology. 2017; https://doi.org/10.1002/hep.29302.
12. P. Nasr M.F. Forsgren S. Ignatova N. Dahlström G. Cedersund O.D. Leinhard et al. Using a 3% proton density fat fraction as a cut-off value increases sensitivity of detection of hepatic Steatosis, based on results from histopathology analysis Gastroenterology 2017 153 1 53 5.e7 1:CAS:528:DC%2BC2sXhtVGkt7vM 10.1053/j.gastro.2017.03.005 28286210 A prospective study that compare liver histology with MRI. Suggest a lower cut off for the diagnosis of fatty liver.
13. R.G. Lee Nonalcoholic steatohepatitis: a study of 49 patients Hum Pathol 1989 20 6 594 598 1:STN:280:DyaL1M3ltlCmsg%3D%3D 10.1016/0046-8177(89)90249-9 2656500
14. E.E. Powell W.G. Cooksley R. Hanson J. Searle J.W. Halliday L.W. Powell The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years Hepatology 1990 11 1 74 80 10.1002/hep.1840110114 2295475
15. M.R. Teli O.F. James A.D. Burt M.K. Bennett C.P. Day The natural history of nonalcoholic fatty liver: a follow-up study Hepatology 1995 22 6 1714 1719 1:STN:280:DyaK28%2FovVyhtQ%3D%3D 10.1002/hep.1840220616 7489979
16. C.A. Matteoni Z.M. Younossi T. Gramlich N. Boparai Y.C. Liu A.J. McCullough Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity Gastroenterology 1999 116 6 1413 1419 1:STN:280:DyaK1M3nvVamtw%3D%3D 10.1016/S0016-5085(99)70506-8 10348825
17. S. Dam-Larsen U. Becker M.B. Franzmann K. Larsen P. Christoffersen F. Bendtsen Final results of a long-term, clinical follow-up in fatty liver patients Scand J Gastroenterol 2009 44 10 1236 1243 1:CAS:528:DC%2BD1MXhsVehtrfM 10.1080/00365520903171284 19670076
18. C.D. Evans K.A. Oien R.N. MacSween P.R. Mills Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury? J Clin Pathol 2002 55 9 689 692 1:STN:280:DC%2BD38vjslCntQ%3D%3D 10.1136/jcp.55.9.689 12195000 1769755
19. L.A. Adams J.F. Lymp J. St Sauver S.O. Sanderson K.D. Lindor A. Feldstein et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study Gastroenterology 2005 129 1 113 121 10.1053/j.gastro.2005.04.014 16012941
20. M. Ekstedt L.E. Franzén U.L. Mathiesen L. Thorelius M. Holmqvist G. Bodemar et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes Hepatology 2006 44 4 865 873 1:CAS:528:DC%2BD28XhtFyqsrzN 10.1002/hep.21327 17006923
21. L.A. Adams S. Harmsen J.L. St Sauver P. Charatcharoenwitthaya F.B. Enders T. Therneau et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study Am J Gastroenterol 2010 105 7 1567 1573 10.1038/ajg.2010.18 20145609 2898908
22. M. Ekstedt H. Hagström P. Nasr M. Fredrikson P. Stål S. Kechagias et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up Hepatology 2015 61 5 1547 1554 1:CAS:528:DC%2BC2MXmslWlt7Y%3D 10.1002/hep.27368 25125077 Number 22 and 23 are two large cohort studies with significant follow-up time. When adjusting for fibrosis, NASH was not associated with mortality.
23. P. Angulo D.E. Kleiner S. Dam-Larsen L.A. Adams E.S. Bjornsson P. Charatcharoenwitthaya et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease Gastroenterology 2015 149 2 389 97.e10 10.1053/j.gastro.2015.04.043 25935633 4516664 See REF 22.
24. G. Musso R. Gambino M. Cassader G. Pagano Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity Ann Med 2011 43 8 617 649 10.3109/07853890.2010.518623 21039302
25. S. Wu F. Wu Y. Ding J. Hou J. Bi Z. Zhang Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis Sci Rep 2016 6 33386 1:CAS:528:DC%2BC2sXps1Khug%3D%3D 10.1038/srep33386 27633274 5026028 Important meta-analysis on the relationship between NAFLD and cardiovascular disease.
26. G. Targher C.D. Byrne A. Lonardo G. Zoppini C. Barbui Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis J Hepatol 2016 65 3 589 600 10.1016/j.jhep.2016.05.013 27212244 Important meta-analysis on the relationship between NAFLD and cardiovascular disease.
27. A.L. Fracanzani S. Tiraboschi G. Pisano D. Consonni A. Baragetti C. Bertelli et al. Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up Atherosclerosis 2016 246 208 213 1:CAS:528:DC%2BC28XhsVKhtbc%3D 10.1016/j.atherosclerosis.2016.01.016 26803429
28. V.W. Wong G.L. Wong J.C. Yeung C.Y. Fung J.K. Chan Z.H. Chang et al. Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: a prospective cohort study Hepatology 2016 63 3 754 763 10.1002/hep.28253 26406278
29. M. Stepanova N. Rafiq H. Makhlouf R. Agrawal I. Kaur Z. Younoszai et al. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD) Dig Dis Sci 2013 58 10 3017 3023 1:CAS:528:DC%2BC3sXhsFWmtrvI 10.1007/s10620-013-2743-5 23775317
30. P. Angulo E. Bugianesi E.S. Bjornsson P. Charatcharoenwitthaya P.R. Mills F. Barrera et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease Gastroenterology 2013 145 4 782 9.e4 10.1053/j.gastro.2013.06.057 23860502 3931256
31. H. Hagström P. Nasr M. Ekstedt S. Kechagias P. Stål P. Bedossa et al. SAF score and mortality in NAFLD after up to 41 years of follow-up Scand J Gastroenterol 2017 52 1 87 91 10.1080/00365521.2016.1230779 27616339
32. • Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. Increased risk of mortality by fibrosis stage in non-alcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017; https://doi.org/10.1002/hep.29085. Important meta-analysis showing increased mortality even in lower stage of fibrosis.
33. •• Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. Journal of hepatology. 2017; Accepted article. The so far largest follow-up study of NAFLD patients with baseline liver biopsy estimating time to decompensation foe each fibrosis stage.
34. P. Bedossa C. Poitou N. Veyrie J.L. Bouillot A. Basdevant V. Paradis et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients Hepatology 2012 56 5 1751 1759 10.1002/hep.25889 22707395
35. N. Bhala P. Angulo D. van der Poorten E. Lee J.M. Hui G. Saracco et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study Hepatology 2011 54 4 1208 1216 10.1002/hep.24491 21688282 3238674
36. M.S. Ascha I.A. Hanouneh R. Lopez T.A. Tamimi A.F. Feldstein N.N. Zein The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis Hepatology 2010 51 6 1972 1978 10.1002/hep.23527 20209604
37. D.L. White F. Kanwal H.B. El-Serag Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review Clin Gastroenterol Hepatol 2012 10 12 1342 59.e2 10.1016/j.cgh.2012.10.001 23041539 3501546
38. Z.M. Younossi M. Otgonsuren L. Henry C. Venkatesan A. Mishra M. Erario et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009 Hepatology 2015 62 6 1723 1730 1:CAS:528:DC%2BC2MXhvFCqtrfL 10.1002/hep.28123 26274335 A very large register based study investigating the disease burden of HCC and the relationship between NAFLD and HCC.
39. V. Ratziu P. Giral F. Charlotte E. Bruckert V. Thibault I. Theodorou et al. Liver fibrosis in overweight patients Gastroenterology 2000 118 6 1117 1123 1:STN:280:DC%2BD3c3psFSntg%3D%3D 10.1016/S0016-5085(00)70364-7 10833486
40. S.A. Harrison S. Torgerson P.H. Hayashi The natural history of nonalcoholic fatty liver disease: a clinical histopathological study Am J Gastroenterol 2003 98 9 2042 2047 10.1111/j.1572-0241.2003.07659.x 14499785
41. E. Fassio E. Alvarez N. Domínguez G. Landeira C. Longo Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies Hepatology 2004 40 4 820 826 15382171
42. L.A. Adams S. Sanderson K.D. Lindor P. Angulo The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies J Hepatol 2005 42 1 132 138 10.1016/j.jhep.2004.09.012 15629518
43. A.Y. Hui V.W. Wong H.L. Chan C.T. Liew J.L. Chan F.K. Chan et al. Histological progression of non-alcoholic fatty liver disease in Chinese patients Aliment Pharmacol Ther 2005 21 4 407 413 1:STN:280:DC%2BD2M%2FotVKmsw%3D%3D 10.1111/j.1365-2036.2005.02334.x 15709991
44. V.W. Wong G.L. Wong P.C. Choi A.W. Chan M.K. Li H.Y. Chan et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years Gut 2010 59 7 969 974 10.1136/gut.2009.205088 20581244
45. R. Pais F. Charlotte L. Fedchuk P. Bedossa P. Lebray T. Poynard et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver J Hepatol 2013 59 3 550 556 1:CAS:528:DC%2BC3sXhtVSls7zE 10.1016/j.jhep.2013.04.027 23665288 A study of NAFLD patients with two liver biopsies with at least 1 year apart. Even NAFL patient can progress histologically.
46. •• McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2014; https://doi.org/10.1016/j.jhep.2014.11.034. Over one hundred NAFLD patients with two liver biopsies were investigated showing that NAFL can progress in fibrosis stage and develop NASH.
47. • Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643–54.e1-9, quiz e39-40. https://doi.org/10.1016/j.cgh.2014.04.014. Important meta-analysis of fibrosis progression.
48. Sanyal A, Harrison S, Ratziu V, Abdelmalek M, Diehl A, Caldwell S et al. Changes in fibrosis, but not the NAFLD Activity Score (NAS), are associated with disease progression in patients with nonalcoholic steatohepatitis (NASH) and advanced fibrosis. The International Liver Congress 2017; Amsterdam: J Hepatol. 2017;S2–S3.
49. McPherson S, Pais R, Valenti L, Schattenberg J, Dufour J-F, Tsochatzis E et al. Further delineation of fibrosis progression in NAFLD: evidence from a large cohort of patients with sequential biopsies. The International Liver Congress 2017; Amsterdam: Journal of Hepatology. 2017;S593.
50. P. Bedossa Histological assessment of NAFLD Dig Dis Sci 2016 61 5 1348 1355 1:CAS:528:DC%2BC28XivFOlu74%3D 10.1007/s10620-016-4062-0 26874689
51. J. Ludwig T.R. Viggiano D.B. McGill B.J. Oh Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease Mayo Clin Proc 1980 55 7 434 438 1:STN:280:DyaL3c3gvVeqtQ%3D%3D 7382552
52. E.M. Brunt C.G. Janney A.M. Di Bisceglie B.A. Neuschwander-Tetri B.R. Bacon Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions Am J Gastroenterol 1999 94 9 2467 2474 1:STN:280:DyaK1MvhtFyisw%3D%3D 10.1111/j.1572-0241.1999.01377.x 10484010
53. D.E. Kleiner E.M. Brunt M. Van Natta C. Behling M.J. Contos O.W. Cummings et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease Hepatology 2005 41 6 1313 1321 10.1002/hep.20701 15915461
54. S. Ballestri F. Nascimbeni E. Baldelli A. Marrazzo D. Romagnoli G. Targher et al. Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases Metabolism 2017 72 57 65 1:CAS:528:DC%2BC2sXmvVKgs7k%3D 10.1016/j.metabol.2017.04.003 28641784
55. L.S. Szczepaniak P. Nurenberg D. Leonard J.D. Browning J.S. Reingold S. Grundy et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population Am J Physiol Endocrinol Metab 2005 288 2 E462 E468 1:CAS:528:DC%2BD2MXhsVCktLg%3D 10.1152/ajpendo.00064.2004 15339742
56. D. Kim W.R. Kim Nonobese fatty liver disease Clin Gastroenterol Hepatol 2017 15 4 474 485 1:CAS:528:DC%2BC28XhsFGnu7zF 10.1016/j.cgh.2016.08.028 27581063
57. Takyar V, Nath A, Beri A, Gharib AM, Rotman Y. How healthy are the “healthy volunteers”? Penetrance of NAFLD in the biomedical research volunteer pool. Hepatology. 2017; https://doi.org/10.1002/hep.29247.